Respuesta :
Resting-state functional connectivity noninvasively measures the association of signaling among brain regions and can be used to identify resting-state networks (RSNs).
What is Pathological Biomarker in Autosomal Dominant Alzheimer's Disease?
The study of rare families with autosomal dominant mutations that cause early-onset AD has had a significant impact on our understanding of the pathophysiology of Alzheimer's disease (AD). Amyloid- peptide (A-) overproduction is brought on by mutations in the APP, PSEN-1, and PSEN-2 genes, which result in early A-peptide deposition in the brain. This, in turn, is thought to set off a series of events that eventually lead to neuronal death, cognitive decline, and dementia. Studies on cerebrospinal fluid (CSF) from people with late-onset AD (LOAD), the most prevalent form of AD, have shown that low CSF A42 and high CSF tau are related to AD brain pathology.
CSF biomarkers in autosomal dominant AD (ADAD) have helped to create a thorough road map of AD pathogenesis, particularly during the preclinical stage, before any cognitive symptoms started to show. To hasten the creation of viable treatments for AD, ongoing pharmacological studies are also employing CSF biomarkers and capitalizing on the special features of ADAD.
Learn more about Alzheimer's disease here:
https://brainly.com/question/14795375
#SPJ4
